Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit

About this update from Cosmos Health Inc.

CHICAGO, June 22, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided a consolidated summary of the contract manufacturing orderbook secured through its wholly owned subsidiary, Cana Laboratories S.A. (“Cana”). Cana has secured a cumulative orderbook of more than 25 million units across agreements with multiple pharmaceutical and wellness partners, comprising various formats including vials, packs, bottles, capsules, and pessaries, and spanning a broad range of therapeutic categories under multi-year terms extending up to ten years. Cana operates its wholly owned, 54,000-square-foot Athens manufacturing facility, licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), enabling it to produce pharmaceuticals, food supplements, cosmetics, biocides, and medical devices for the European Union and international markets. The Company has invested approximately $5.5 million in upgrading and modernizing the facility — including new machinery, equipment, IT infrastructure, and quality management systems — and recently inaugurated a new, state-of-the-art ACG capsule-filling production line that further expands its capabilities and capacity. At full capacity, the contract manufacturing division is positioned to generate over $10 million in recurring annual profit. Contract Manufacturing Orderbook SummaryCana’s contract manufacturing orders include, among others: The orderbook spans central nervous system, musculoskeletal, dermatological, vitamin, anti-inflammatory, oncology-support, women’s health, antiseptic, and wellness categories, reducing dependence on any single product or partner. The Company views contract manufacturing as a high-margin, recurring-revenue segment that provides strong, long-term cash flow visibility, including contracts extending up to ten years with established partners. Contract manufacturing is a central element of Cosmos Health’s vertically integrated model. The same EU-licensed facility that produces the Company’s proprietary pharmaceutical and nutraceutical brands also provides contract manufacturing (CMO) services to third-party partners, allowing Cosmos Health to maximize facility utilization, spread fixed costs across a larger production base, and gener...

View stock analysis, news, and events for Cosmos Health Inc.